Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression

Journal of Virology

Volumn 74, Issue 13, 2000, Pages 6132-6146

  Pepperl, Sandra ^a   Münster, Jürgen ^a   Mach, Michael ^b   Harris, J Robin ^a   Plachter, Bodo ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; DENSE BODY; GENE EXPRESSION; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

3T3 CELLS; ANIMALS; ANTIBODIES, VIRAL; ANTIGEN PRESENTATION; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOTOXICITY, IMMUNOLOGIC; DEFECTIVE VIRUSES; GENE EXPRESSION; H-2 ANTIGENS; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PHOSPHOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TUMOR CELLS, CULTURED; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 18744436552     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.13.6132-6146.2000     Document Type: Article

References (90)

1. Adler, S. P., S. H. Hempfling, S. E. Starr, S. A. Plotkin, and S. Riddell. 1998. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr. Infect. Dis. J. 17:200-206.
2. Adler, S. P., S. A. Plotkin, E. Gonczol, M. Cadoz, C. Meric, J. B. Wang, P. Dellamonica, A. M. Best, J. Zahradnik, S. Pincus, K. Berencsi, W. I. Cox, and Z. Gyulai. 1999. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis. 180:843-846.
3. Adler, S. P., S. E. Starr, S. A. Plotkin, S. H. Hempfling, J. Buis, M. L. Manning, and A. M. Best. 1995. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 171:26-32.
4. Andreoni, M., M. Faircloth, L. Vugler, and W. J. Britt. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J. Virol. Methods 23:157-167.
5. Baldick, C. J., Jr., and T. Shenk. 1996. Proteins associated with purified human cytomegalovirus particles. J. Virol. 70:6097-6105.
6. Banks, T., B. Huo, K. Kousoulas, R. Spaete, C. Pachl, and L. Pereira. 1989. A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. J. Gen. Virol. 70:979-985.
7. Beninga, J., B. Kropff, and M. Mach. 1995. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T cell response. J. Gen. Virol. 76:153-160.
8. Boppana, S. B., and W. J. Britt. 1996. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 222:293-296.
9. Bradley, L. M., K. Yoshimoto, and S. L. Swain. 1995. The cytokines IL-4, IFN-gamma, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro. J. Immunol. 155:1713-1724.
10. Britt, W., J. Fay, J. Seals, and C. Kensil. 1995. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J. Infect. Dis. 171:18-25.
11. Britt, W. J. 1996. Vaccines against human cytomegalovirus: time to test. Trends Microbiol. 4:34-38.
12. Britt, W. J., and C. A. Alford. 1996. Cytomegalovirus, p. 2493-2524. In B. N. Fields, P. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
13. Craighead, J. E., R. E. Kanich, and J. D. Almeida. 1972. Nonviral microbodies with viral antigenicity produced in cytomegalovirus-infected cells. J. Virol. 10:766-775.
14. Diamond, D. J., J. York, J. Y. Sun, C. L. Wright, and S. J. Forman. 1997. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751-1767.
15. Elek, S. D., and H. Stern. 1974. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet i:1-5.
16. Endresz, V., L. Kari, K. Berencsi, C. Kari, Z. Gyulai, C. Jeney, S. Pincus, U. Rodeck, C. Meric, S. A. Plotkin, and E. Gonczol. 1999. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 17:50-58.
17. Falagas, M. E., C. Paya, R. Ruthazer, A. Badley, R. Patel, R. Wiesner, J. Griffith, R. Freeman, R. Rohrer, B. G. Werner, and D. R. Snydman. 1998. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 66:1020-1028.
18. Falagas, M. E., D. R. Snydman, J. Griffith, R. Ruthazer, and B. G. Werner. 1997. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group. Ann. Intern. Med. 126:275-279.
19. Falagas, M. E., D. R. Snydman, R. Ruthazer, J. Griffith, B. G. Werner, R. Freeman, and R. Rohrer. 1997. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin. Transplant. 11:432-437.
20. Feltquate, D. M., S. Heaney, R. G. Webster, and H. L. Robinson. 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158:2278-2284.
21. Fiala, M., R. W. Honess, D. C. Heiner, J. W. Heine, Jr., J. Murnane, R. Wallace, and L. B. Guze. 1976. Cytomegalovirus proteins. I. Polypeptides of virions and dense bodies. J. Virol. 19:243-254.
22. Forghani, B., and N. J. Schmidt. 1980. Humoral immune response to virions and dense bodies of human cytomegalovirus determined by enzyme immunofluorescence assay. J. Med. Virol. 6:119-127.
23. Fowler, K. B., S. Stagno, R. F. Pass, W. J. Britt, T. J. Boll, and C. A. Alford. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med. 326:663-667.
24. Gibson, W., and A. Irmiere. 1984. Selection of particles and proteins for use as human cytomegalovirus subunit vaccines. Birth Defects 20:305-324.
25. Gonczol, E., K. Berensci, S. Pincus, V. Endresz, C. Merk, E. Paoletti, and S. A. Plotkin. 1995. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13:1080-1085.
26. Gonczol, E., J. Ianacone, W. Z. Ho, S. Starr, B. Meignier, and S. Plotkin. 1990. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8:130-136.
27. Grefte, J. M., B. T. van der Gun, S. Schmolke, M. van der Giessen, W. J. van Son, B. Plachter, G. Jahn, and T. H. The. 1992. The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J. Gen. Virol. 73:2923-2932.
28. Harris, J. R., and R. W. Horne. 1991. Negative staining, p. 203-208. In J. R. Harris (ed.), Electron microscopy in biology. IRL Press, Oxford, England.
29. Harris, J. R. 1997. Negative staining and cryoelectron microscopy: the thin film techniques. Bios Scientific Publishers, Oxford, England.
30. Holtappels, R., J. Podlech, G. Geginat, H. P. Steffens, D. Thomas, and M. J. Reddehase. 1998. Control of murine cytomegalovirus in the lungs: relative but not absolute immunodominance of the immediate-early 1 nonapeptide during the antiviral cytolytic T-lymphocyte response in pulmonary infiltrates. J. Virol. 72:7201-7212.
31. Irmiere, A., and W. Gibson. 1983. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology 130:118-133.
32. Jahn, G., H. P. Harthus, M. Bröker, B. Borisch, B. Platzer, and B. Plachter. 1990. Generation and application of a monoclonal antibody raised against a recombinant cytomegalovirus-specific polypeptide. Klin. Wochenschr. 68: 1003-1007.
33. Jahn, G., B. C. Scholl, B. Traupe, and B. Fleckenstein. 1987. The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties. J. Gen. Virol. 68:1327-1337.
34. + T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73:8179-8184.
35. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93:2879-2883.
36. Koszinowski, U. H., M. J. Reddehase, and M. Del Val. 1992. Principles of cytomegalovirus antigen presentation in vitro and in vivo. Semin. Immunol. 4:71-79.
37. Kovacsovics, B. M., K. Clark, B. Benacerraf, and K. L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA 90:4942-4946.
38. Kranz, D. M., S. Tonegawa, and H. N. Eisen. 1984. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 81:7922-7926.
39. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
40. LaFace, D. M., M. Vestberg, Y. Yang, R. Srivastava, J. DiSanto, N. Flomenberg, S. Brown, L. A. Sherman, and P. A. Peterson. 1995. Human CD8 transgene regulation of HLA recognition by murine T cells. J. Exp. Med. 182:1315-1325.
41. Leland, D. S., and M. L. V. French. 1988. Virus isolation and identification, p. 39-59. In E. H. Lennette, P. Halonen, and F. A. Murphy (ed.), Laboratory diagnosis of infectious diseases. Springer, New York, N.Y.
42. Li, C., X. Yang, W. Tu, and S. R. Riddell. 1997. Human cytomegalovirus matrix protein PP150 is efficiently presented as one of target antigens for cytotoxic T lymphocyte recognition. Chin. Med. J. 110:397-400.
43. + virus-specific cytotoxic T lymphocytes. J. Med. Virol. 43:103-110.
44. Meyer, H., V. A. Sundqvist, L. Pereira, and M. Mach. 1992. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J. Gen. Virol. 73:2375-2383.
45. O'Garra, A., and K. Murphy. 1994. Role of cytokines in determining T-lymphocyte function. Curr. Opin. Immunol. 6:458-466.
46. Oh, Y. K., C. V. Harding, and J. A. Swanson. 1997. The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation. Vaccine 15:511-518.
47. Pepperl, S., G. Benninger-Doring, S. Modrow, H. Wolf, and W. Jilg. 1998. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J. Virol. 72:8644-8649.
48. Pfeifer, J. D., M. J. Wick, R. L. Roberts, K. Findlay, S. J. Normark, and C. V. Harding. 1993. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361:359-362.
49. Plotkin, S. A. 1999. Vaccination against cytomegalovirus, the changeling demon. Pediatr. Infect. Dis. J. 18:313-325.
50. Plotkin, S. A., S. E. Starr, H. M. Friedman, K. Brayman, S. Harris, S. Jackson, N. B. Tustin, R. Grossman, D. Dafoe, and C. Barker. 1991. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann. Intern. Med. 114:525-531.
51. Plotkin, S. A., S. E. Starr, H. M. Friedman, E. Gonczol, and R. E. Weibel. 1989. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis. 159:860-865.
52. Plotkin, S. A., R. E. Weibel, G. Alpert, S. E. Starr, H. M. Friedman, S. R. Preblud, and J. Hoxie. 1985. Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. J. Infect. Dis. 151:737-739.
53. Quinnan, G. V. J., N. Kirmani, A. H. Rook, J. F. Manischewitz, L. Jackson, G. Moreschi, G. W. Santos, R. Saral, and W. H. Burns. 1982. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307:7-13.
54. Reddehase, M. J., G. M. Keil, and U. H. Koszinowski. 1984. The cytolytic T lymphocyte response to the murine cytomegalovirus. I. Distinct maturation stages of cytolytic T lymphocytes constitute the cellular immune response during acute infection of mice with the murine cytomegalovirus. J. Immunol. 132:482-489.
55. Reddehase, M. J., G. M. Keil, and U. H. Koszinowski. 1984. The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur. J. Immunol. 14:56-61.
56. Reddehase, M. J., and U. H. Koszinowski. 1984. Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection. Nature 312:369-371.
57. Reddehase, M. J., W. Mutter, K. Münch, H. J. Buhring, and U. H. Koszinowski. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61: 3102-3108.
58. Reiner, S. L., and R. A. Seder. 1995. T helper cell differentiation in immune response. Curr. Opin. Immunol. 7:360-366.
59. Reusser, P., G. Cathomas, R. Attenhofer, M. Tamm, and G. Thiel. 1999. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J. Infect. Dis. 180:247-253.
60. Reusser, P., S. R. Riddell, J. D. Meyers, and P. D. Greenberg. 1991. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373-1380.
61. Riddell, S. R., M. Rabin, A. P. Geballe, W. J. Britt, and P. D. Greenberg. 1991. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus docs not require endogenous viral gene expression. J. Immunol. 146:2795-2804.
62. Riddell, S. R., M. Rabin, A. P. Geballe, W. J. Britt, and P. D. Greenberg. 1991. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146:2795-2804.
63. Riddell, S. R., K. S. Watanabe, J. M. Goodrich, C. R. Li, M. E. Agha, and P. D. Greenberg. 1992. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238-241.
64. Riegler, S., H. Hebart, H. Einsele, P. Brossart, G. Jahn, and C. Sinzger. 2000. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J. Gen. Virol. 81:393-399.
65. Rony, C., and W. Gibson. 1986. Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus. J. Virol. 59:714-727.
66. Rubin, R. H. 1990. Impact of cytomegalovirus infection on organ transplant recipients. Rev. Infect. Dis. 12(Suppl. 7):S754-S766.
67. Rüger, B., S. Klages, B. Walla, J. Albrecht, B. Fleckenstein, P. Tomlinson, and B. Barrell. 1987. Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J. Virol. 61:446-453.
68. Sarov, I., and I. Abady. 1975. The morphogenesis of human cytomegalovirus: isolation and polypeptide characterization of cytomegalovirions and dense bodies. Virology 66:464-473.
69. Sarov, I., A. M. Larsen, I. Heron, and H. K. Andersen. 1978. Stimulation of human lymphocytes by cytomegalovirions and dense bodies. Med. Microbiol. Immunol. 166:81-89.
70. Schmolke, S., P. Drescher, G. Jahn, and B. Plachter. 1995. Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport. J. Virol. 69:1071-1078.
71. Schoppel, K., C. Schmidt, H. Einsele, H. Hebart, and M. Mach. 1998. Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J. Infect. Dis. 178:1233-1243.
72. + T cells. Annu. Rev. Immunol. 12:635-673.
73. Sherman, L. A., S. V. Hesse, M. J. Irwin, D. La Face, and P. Peterson. 1992. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258:815-818.
74. Smyth, R. L., J. P. Scott, L. K. Borysiewicz, L. D. Sharples, S. Stewart, T. G. Wreghitt, J. J. Gray, T. W. Higenbottam, and J. Wallwork. 1991. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J. Infect. Dis. 154:1045-1050.
75. Snydman, D. R., B. G. Werner, H. C. Meissner, S. H. Cheeseman, J. Schwab, F. Bednarek, J. L. Kennedy, Jr., M. Herschel, A. Magno, M. J. Levin, et al. 1995. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr. Infect. Dis. J. 14:34-40.
76. Speckner, A., D. Glykofrydes, M. Ohlin, and M. Mach. 1999. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J. Gen. Virol. 80:2183-2191.
77. Speidel, K., W. Osen, S. Faath, I. Hilgert, R. Obst, J. Braspenning, F. Momburg, G. J. Hämmerling, and H. G. Rammensee. 1997. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: conditions, efficiency, and relation to antibody responses. Eur. J. Immunol. 27:2391-2399.
78. Starr, S. E., J. P. Glazer, H. M. Friedman, J. D. Farquhar, and S. A. Plotkin. 1981. Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J. Infect. Dis. 143:585-589.
79. Stinski, M. F. 1976. Human cytomegalovirus: glycoproteins associated with virions and dense bodies. J. Virol. 19:594-609.
80. Talbot, P., and J. D. Almeida. 1977. Human cytomegalovirus: purification of enveloped virions and dense bodies. J. Gen. Virol. 36:345-349.
81. Topilko, A., and S. Michelson. 1994. Hyperimmediate entry of human cytomegalovirus virions and dense bodies into human fibroblasts. Res. Virol. 145:75-82.
82. Urban, M., M. Klein, W. J. Britt, E. Hassfurther, and M. Mach. 1996. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J. Gen. Virol. 77:1537-1547.
83. Utz, U., W. Britt, L. Vugler, and M. Mach. 1989. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J. Virol. 63:1995-2001.
84. Vitiello, A., D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007-1015.
85. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic hone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
86. Werner, B. G., D. R. Snydman, R. Freeman, R. Rohrer, N. L. Tilney, and R. L. Kirkman. 1993. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The Treatment IND Study Group. Transplant. Proc. 25:1441-1443.
87. Wills, M. R., A. J. Carmichael, K. Mynard, X. Jin, M. P. Weekes, B. Plachter, and J. G. Sissons. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70:7569-7579.
88. Winkler, M., and T. Stamminger. 1996. A specific subform of the human cytomegalovirus transactivator protein pUL69 is contained within the tegument of virus particles. J. Virol. 70:8984-8987.
89. Wolf, D. G., A. Honigman, J. Lazarovits, E. Tavor, and A. Panet. 1998. Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase. Arch. Virol. 143:1223-1232.
90. Yeager, A. S., F. C. Grumet, E. B. Hafleigh, A. M. Arvin, J. S. Bradley, and C. G. Prober. 1981. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr. 98:281-287.